Clinical Trial Update: Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study assessing the bioequivalence between two formulations of Biphasic Insulin Aspart 50 was conducted in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Biphasic Insulin Aspart 50 (BIAsp 50) (biphasic insulin aspart 50)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED